Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by OSE Immunotherapeutics OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update September 26, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer September 10, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis July 24, 2024 From OSE Immunotherapeutics Via GlobeNewswire Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 July 03, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ July 01, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies June 24, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21) June 20, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth June 19, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse June 12, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant June 05, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics Provides Business and Corporate Update May 30, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases May 22, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective April 16, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology April 02, 2024 From OSE Immunotherapeutics Via GlobeNewswire OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update March 27, 2024 From OSE Immunotherapeutics Via Business Wire OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook January 19, 2024 From OSE Immunotherapeutics Via Business Wire OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody October 23, 2023 From OSE Immunotherapeutics Via Business Wire OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology September 11, 2023 From OSE Immunotherapeutics Via Business Wire OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist: July 06, 2023 From OSE Immunotherapeutics Via Business Wire OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment July 04, 2023 From OSE Immunotherapeutics Via Business Wire OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer June 20, 2023 From OSE Immunotherapeutics Via Business Wire OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology April 20, 2023 From OSE Immunotherapeutics Via Business Wire OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies February 15, 2023 From OSE Immunotherapeutics Via Business Wire OSE Immunotherapeutics annonce sa participation aux événements Investisseurs au cours du 1er trimestre 2023 January 03, 2023 From OSE Immunotherapeutics Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.